Drugs & Medications

MSA Drug Repurposing Review Highlighted Ubiquinol and Exenatide Signals

by
MSA Drug Repurposing Review Highlighted Ubiquinol and Exenatide Signals

TL;DR: A 2026 review in Translational Neurodegeneration found that most repurposed multiple system atrophy drugs failed to show disease-slowing effects in trials, while ubiquinol produced the clearest placebo-controlled motor-progression signal. Key Findings No proven disease-modifying therapy: Multiple system atrophy remains a rapidly progressive neurodegenerative disease without an approved treatment that slows progression. Four target classes …

Read more

Psychedelic Treatment Media Coverage Used More Positive Tone

by
Psychedelic Treatment Media Coverage Used More Positive Tone

TL;DR: A 2026 Scientific Reports study of 6,805 English-language media reports found that psychedelic-treatment coverage for depression and PTSD used more positive tone than antidepressant coverage, while antidepressant coverage used more risk and negative-emotion language. Key Findings 6,805 media reports: Researchers analyzed English-language newspaper coverage from 2017 to 2024 using LexisNexis and natural language processing. …

Read more

Monthly Lecanemab Maintained Alzheimer’s Blood Biomarker Changes After 18 Months

by
Monthly Lecanemab Maintained Alzheimer's Blood Biomarker Changes After 18 Months

TL;DR: A 2026 study in Alzheimer’s & Dementia: Translational Research & Clinical Interventions used lecanemab pharmacokinetic/pharmacodynamic modeling in early Alzheimer’s disease and found that blood biomarkers worsened after treatment stopped, while monthly maintenance dosing after 18 months was predicted to preserve most p-tau181 and GFAP, an astrocyte-inflammation protein. Key Findings Three plasma biomarkers improved: Lecanemab …

Read more

Lisdexamfetamine Overdose Caused Delayed Severe Stress Cardiomyopathy in a Teen Case

by
Lisdexamfetamine Overdose Caused Delayed Severe Stress Cardiomyopathy in a Teen Case

TL;DR: A 2026 Critical Care Explorations paper described a 17-year-old girl whose intentional lisdexamfetamine overdose was followed by delayed severe heart failure, with left ventricular ejection fraction falling below 20% before recovery over months. Key Findings Delayed cardiac collapse: The patient first appeared stable after treatment, then worsened again about 24 hours after ingestion. Severe …

Read more

GLP-1 Weight Loss Drew More Stigma Through Shortcut Beliefs

by
GLP-1 Weight Loss Drew More Stigma Through Shortcut Beliefs

TL;DR: A 2026 study in Stigma and Health found that women who lost 15% of body weight with GLP-1 receptor agonists, medications such as semaglutide that mimic a metabolic hormone involved in appetite and glucose signaling, were judged more harshly than women who lost the same amount through diet and exercise. Key Findings Medication-assisted loss …

Read more

Metoclopramide and Antipsychotics Led Drug-Induced Dystonia Reports

by
Metoclopramide and Antipsychotics Led Drug-Induced Dystonia Reports

TL;DR: A 2026 study in Health Science Reports found that metoclopramide and several antipsychotics were strongly overrepresented in FDA adverse-event reports for drug-induced dystonia, with many reported cases appearing within the first month after drug initiation. Key Findings 28,938 dystonia reports: Researchers analyzed FDA Adverse Event Reporting System records from the first quarter of 2004 …

Read more

Smoking and Quitting Shifted Clozapine Metabolism in Schizophrenia

by
Smoking and Quitting Shifted Clozapine Metabolism in Schizophrenia

TL;DR: A 2026 study in Neuropsychopharmacology Reports found that repeated cigarette smoking and quitting shifted clozapine metabolism in one Japanese man with treatment-resistant schizophrenia, with the dose-adjusted clozapine level falling during smoking periods. Key Findings One patient was followed across five periods: Researchers tracked a Japanese man in his 40s across smoking, quitting, smoking, quitting, …

Read more

CBD Psychiatric Claims Need Standardized Products and Safety Monitoring

by
CBD Psychiatric Claims Need Standardized Products and Safety Monitoring

TL;DR: A 2026 paper in Neuropsychopharmacology argued that cannabidiol (CBD), a non-intoxicating cannabis compound, has plausible psychiatric and neurological uses, but clinical claims need standardized products, exposure tracking, and safety monitoring before retail CBD can be treated like medicine. Key Findings Epilepsy evidence is strongest: Approved prescription CBD has the clearest support in rare pediatric …

Read more

Catecholamine GPCR Ligand Selectivity Was Swapped by Small Residue Sets

by
Catecholamine GPCR Ligand Selectivity Was Swapped by Small Residue Sets

TL;DR: A 2026 Nature Communications study found that small sets of amino-acid changes could swap ligand preference between beta2 adrenergic and D1 dopamine receptors, showing that receptor selectivity depends on both the binding pocket and surrounding structural interfaces. Key Findings 120 receptor mutants: Researchers tested 120 engineered catecholamine receptor mutants across beta2 adrenergic and D1 …

Read more

Bumetanide Study Captured Sensory-Reactivity Changes in Neurodevelopmental Disorders

by
Bumetanide Study Captured Sensory-Reactivity Changes in Neurodevelopmental Disorders

TL;DR: A 2026 preprint in medRxiv found that a parent-cocreated sensory-reactivity outcome set captured anxiety, mood, sleep, fatigue, cognition, and peer-relationship changes during bumetanide treatment in children and adolescents with neurodevelopmental disorders, but the unmasked design means the results should not be treated as definitive drug efficacy evidence. Key Findings Treatment cohort: 113 children and …

Read more

+ Load more